Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
Primary Care
Are there any recommendations for restarting JAKi after a provoked DVT?
Related Questions
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
Would you re-challenge a patient with Rituximab who responded well in terms of their RA but developed symptomatic tachycardia after their first infusion?
How do you approach treatment selection in patients with rheumatoid arthritis and severe COPD?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
How do you approach the management of a patient with RA on methotrexate who has gingivitis or or frequent cavities?
For patients with obesity and elevated alk phos who have RA, do you check a fibroscan or serum NASH fibrosure test before starting methotrexate or leflunomide?
Would you escalate therapy in a patient with rheumatoid arthritis without synovitis, but a new rheumatoid nodule?
How do you manage oral ulcers as a side effect from leflunomide?
What is your approach to biologic therapy in older adults (80+) and CKD with RA?
